"Lp(a) represents the most important potential potential paradigm shift in cardiovascular disease prevention that we'll experience over the next five to 10 years," Seth Baum, MD, explained in a new interview.

"We cannot accept a system where only those with means can benefit from life-changing drugs. We are a wealthy nation that spends trillions on healthcare. We must ensure that income and wealth do not determine access," explained JACC Editor-in-Chief Harlan M. Krumholz, MD.

Tirzepatide and semaglutide are getting the attention now, but orforglipron could be the next go-to drug for patients hoping to lose weight and improve their heart health—no injections required.

The interventional cardiologist was accused of prescribing a variety of drugs to his family and friends, but then picking them up himself for his own personal use. This settlement officially resolves those allegations. 

The American Pharmacists Association is being labeled as a biased special interest group under new rules for the CDC Advisory Committee on Immunization Practices, a move that seems to be politically motivated when APhA did not support changes in COVID vaccines earlier this year. 

The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.

Tirzepatide met the primary endpoint of non-inferiority versus dulaglutide, with an 8% lower rate of MACE events included cardiovascular death, heart attack or stroke, while delivering greater reductions in A1C and weight.

Giving colchicine to patients prior to TAVR may reduce the risk of certain conduction disturbances, according to new research published in the Journal of the American Heart Association. It does not, however, improve survival.